Despite decades of clinical trials showing lack of efficacy for various neuroprotective agents for acute ischemic stroke, its global market continues to expand significantly. In the Philippines, the most heavily utilized medications include Citicoline, NeuroAiD, Edaravone, and Cerebrolysin. This study aims to systematically review the clinical evidence on the efficacy and safety of these interventions compared to placebo and to rank its effectivity using network meta-analysis. Fourteen studies were included after screening 135 clinical trials with majority of the studies having mild to moderate risk of bias. Results showed that the neuroprotectants are safe but did not have an advantage compared to placebo in terms of improvement of clinical outcomes (modified Rankin score (mRS) 0-1, National Institutes of Health Stroke Scale and Barthel Index) after three months. Across these efficacy measures, Cerebrolysin, Citicoline, NeuroAiD and Edaravone appear to be similar to placebo but Cerebrolysin is not better compared to placebo in terms of achieving an mRS of 0-2 after three months. This study adds to the wealth of knowledge that routine use of these interventions in acute ischemic stroke particularly for resource-deprived countries like the Philippines is not recommended.